Epilepsja jako marker upośledzenia poznawczego w angiopatii amyloidowej mózgu: dowody z dużej wieloośrodkowej grupy pacjentów

PubMed➕ 10.10.2026Seizure

Epilepsy as a marker of cognitive decline in cerebral amyloid angiopathy: Evidence from a large multi-institutional cohort

W skrócie

Badacze analizowali dane ponad 2700 pacjentów z angiopatią amyloidową mózgu (chorobą naczyń mózgowych) i stwierdzili, że u osób z epilepsją ryzyko utraty funkcji poznawczych, takich jak pamięć czy myślenie, było wyższe. Epilepsja pojawiła się u około 27% pacjentów z tą chorobą, ale nie wpłynęła na przeżywalność pacjentów w obserwowanym okresie.

Oryginalny abstract (angielski)

INTRODUCTION: Cerebral amyloid angiopathy (CAA) is an amyloid mediated cortical and leptomeningeal small-vessel disease that commonly presents with lobar intracerebral hemorrhage, cognitive impairment, and transient neurological symptoms. Epilepsy occurs in 20-33 % of patients with CAA, but their association with cognitive function and survival remains incompletely defined. METHODS: We conducted a retrospective cohort study using the Mayo Clinic Platform, which contains multi-institutional de-identified longitudinal electronic health records. Adult patients (≥18 years) with CAA were identified using ICD-10 code I68.0 and natural language processing of clinical notes including Boston criteria 2.0. Epilepsy was defined per ILAE criteria with ICD-10 codes and documentation in clinical notes, and cognitive dysfunction diagnosis was confirmed using patient history. Propensity score matching (1:1) was performed at the date of CAA diagnosis. Time-to-event outcomes were estimated using Kaplan-Meier methods and Cox proportional hazards regression for 60 months follow-up. RESULT: Among the 2717 patients with CAA (mean age 74.5 years), 733 patients (27.0 %) had epilepsy. 673 propensity score-matched pairs were included in the final analysis. Epilepsy was associated with a higher risk of cognitive dysfunction (HR 1.34, 95 % CI 1.13-1.60). No statistically significant difference was noted in all-cause mortality between cohorts (HR 1.07, 95 % CI 0.86-1.33). CONCLUSION: Epilepsy in patients with CAA was associated with higher risk of cognitive decline. There was no difference in all-cause mortality, but the confidence interval does not exclude a clinically meaningful effect in either direction. These findings highlight patients with epilepsy as a subgroup of CAA cases with increased risk for cognitive decline. Prospective studies with validated cognitive assessments are needed to confirm this association.

Metadane publikacji

Journal
Seizure
Data publikacji
05.10.2026
PMID
42854618
DOI
10.1016/j.seizure.2026.10.003
Autorzy
Khand Y, Vallamchetla SK, Patel A, Safa A, Tatit CP, Day GS, Lin MP, Block CK, Tatum WO, Freund B
Słowa kluczowe
Cerebral amyloid angiopathy, Cognitive decline, Epilepsy, Intracerebral hemorrhage, Seizures
Źródło
PubMed